This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
2023 Information Coming Soon!

2023 Information Coming Soon!

Thank you for joining us in 2022! Look out for more information on 2023 dates coming soon...

EUROPE'S LEADING ANTIBODY CONFERENCE FOR ACCELERATING NEXT-GENERATION ANTIBODIES TO COMMERCIAL SUCCESS

Key Updates on Polyclonal Antibody Therapeutics, Non-Cancer Indications, Alternative Scaffolds, Multispecifics, T-Cells, Machine Learning, and Much More!

THE 2022 AGENDA: CUTTING-EDGE ANTIBODY & PROTEIN TOPICS:

Dive into 8 topic streams with the option to add-on 2 brand new workshop options at the 2022 Antibody Engineering & Therapeutics Europe event. 

  • Polyclonal Antibody Therapeutics: Mechanisms and Perspectives
  • Developing Antibodies to Non-Cancer Indications (Including COVID Antibodies)
  • Alternative Scaffolds (VHH, Nanobodies, Non- IgG, Fibronectin Binders, Peptides)
  • Machine Learning Approaches for Antibody Engineering
  • Strategies for Improving the Therapeutic Window of Antibody Drugs
  • Multispecifics and T-Cell Engagers
  • Finding the Right Antibody (Arrays, MS, Display Technologies)
  • From Antibody Discovery to Screening and Developability
  • Workshop A: Finding the Right Antibody
  • Workshop B: From Antibody Discovery to Screening and Developability

BE A PART OF THE DISCUSSION: SHOWCASE YOUR LATEST RESEARCH WITH A POSTER PRESENTATION!

Highlight your organization’s latest research by presenting a scientific poster in our poster presentation hall in Amsterdam, or host your presentation PDF in our digital poster hall.

Anyone planning to present a poster MUST:

  1. Add the poster presentation add-on option to their conference pass
  2. Submit a poster presentation abstract prior - which must be approved by the Antibody Content Team. You can submit your abstract for approval by clicking this link. 

All poster presentation abstract submissions will need to be completed and submitted by 13th May, 2022.

WHO WILL YOU BE NETWORKING WITH?

Download the job titles and companies that have previously attended Antibody Engineering & Therapeutics Europe to get a sense of who you will be networking with this year.

About The Antibody Society

The Antibody Society is an international, non-profit representing individuals and organizations involved in antibody-related research and development. The Society has a variety of initiatives and working groups focused on improving the antibody field.

We are:

- Creating opportunities for education and networking;

- Monitoring and reporting advances in the commercial pipeline for antibody and CAR-T therapeutics;

- Creating standards for characterizing antibody and T-cell receptor repertoires, and engaging this field;

- Engaging government and international agencies on matters concerning the antibody community;

 Please join us!

Connecting with Key Antibody Decision Makers

Put yourself in front of key decision makers within the antibody engineering landscape at Antibody Engineering & Therapeutics Europe.
We provide flexible, tailored solutions to optimize your investment. Below are some examples of how you can get involved at the event. There's no better place to network with core audiences and make lasting connections.

To learn more about available opportunities or to begin building your custom sponsorship package, please contact:

Blake Shuka
blake.shuka@informa.com | (+1) 212-600-3451

DOWNLOAD WHITE PAPER

CAR-T and T-cell receptor (TCR) cell therapies are some of the most exciting emerging therapies on the market today, and their engineering strategies are crucial. This whitepaper discusses recent developments in CAR and TCR engineering and the overlap with antibody engineering, including:

  • Companies leading the way in TCR and T cell engineering
  • Novel platforms and enabling technologies
  • Technologies for Engineering CAR T cells
  • Technologies for Engineering TCRs (T cell receptors)
  • Lessons antibody engineers can learn from TCR and CAR T cell engineers

Paul W.H.I. Parren, Ph.D.

Board Member of the Antibody Society and Conference Committee Co-Chair

Leiden University Medical Center and Lava Therapeutics

“I feel honored to coordinate the scientific programming of the renowned Antibody Engineering and Therapeutics EUROPE conference on behalf of The Antibody Society. A team of stellar scientific advisors put together a program this year that is not-to-be-missed. I am therefore delighted that Informa Connect is digitizing this year’s event to allow it to move forward under these challenging circumstances.”